AstraZeneca recorded a net profit of 10.2 billion dollars in 2025, with a 45% increase due to sales of cancer drugs.

AstraZeneca, the British pharmaceutical giant, announced on Tuesday a 45% increase in net profit in 2025, reaching 10.2 billion dollars, compared to 7 billion dollars in the previous year. Revenues grew by 9%, reaching 58.7 billion dollars, due to strong sales of cancer drugs. CEO Pascal Soriot highlighted the solid commercial performance and excellent deliveries from the company's pipeline, expressing confidence that AstraZeneca will achieve an annual revenue of 80 billion dollars by the end of the decade.

The company is expanding its presence in the US and China markets, investing 15 billion dollars in China by 2030 and aiming for the US to represent half of global revenues by 2030. Additionally, AstraZeneca has begun to list its shares on the New York Stock Exchange to attract more investors, in the context of threats of tariffs imposed by President Trump on the pharmaceutical industry.